BerGenBio
Private placement to support randomised Phase II trialsHutchison China MediTech
Surufatinib on track for potential 2020 China approvalHutchison China MediTech
Impressive data means SANET-ep trial stopped earlyScancell
Vulpes investment brings £3.88m in new fundsBerGenBio
ASCO: more supportive data for bemcentinibMereo BioPharma
Encouraging interim BPS-804 data in OIHutchison China MediTech
Timing is right for a Hong Kong debutNexstim
Getting back on the front footScancell
SCIB2 to use new nanoparticle formulationMereo BioPharma
Focus shifts back to imminent data